PDS Biotechnology (PDSB) announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate cancer will be discussed during an oral presentation at the 12th Annual Meeting of the International Cytokine & Interferon Society in Seoul, South Korea.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PDSB:
- Biotech Alert: Searches spiking for these stocks today
- PDS Biotechnology’s Versamune® HPV Shows Promise in Phase 2 Trial
- PDS reports updated data from the IMMUNOCERV Phase 2 clinical trial
- PDS Biotech Advances with Promising Versamune® HPV Trial Results
- PDS Biotechnology announces updates data from VERSATILE-002 trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
